A5023814919- Fibroblast Growth Factor Research
- Proteoglycans and glycosaminoglycans research
- Epigenetics and DNA Methylation
- Kruppel-like factors research
- Neuroendocrine Tumor Research Advances
- Nanoplatforms for cancer theranostics
- PI3K/AKT/mTOR signaling in cancer
- Monoclonal and Polyclonal Antibodies Research
- Cancer Cells and Metastasis
- Hippo pathway signaling and YAP/TAZ
- Eosinophilic Disorders and Syndromes
- Platelet Disorders and Treatments
- Social Media in Health Education
- Cellular transport and secretion
- Magnolia and Illicium research
- Ubiquitin and proteasome pathways
- Photodynamic Therapy Research Studies
- Mast cells and histamine
University of Wrocław
2018-2024
Fibroblast growth factors (FGFs) via their receptors (FGFRs) transduce signals from the extracellular space to cell interior, modulating pivotal cellular processes such as proliferation, motility, metabolism and death. FGF superfamily includes a group of fibroblast factor homologous (FHFs), proteins whose function is still largely unknown. Since FHFs lack signal sequence for secretion are unable induce FGFR-dependent these were considered intracellular that not involved in transduction...
Fibroblast growth factor receptor 1 (FGFR1) is a plasma membrane protein that transmits signals from the extracellular environment, regulating cell homeostasis and function. Dysregulation of FGFR1 leads to development human cancers noncancerous diseases. Numerous tumors overproduce FGFR1, making this perspective target for cancer therapies. Antibody-drug conjugates (ADCs) are highly potent selective anticancer agents. ADCs composed antibodies (targeting factors) fused cytotoxic drugs...
Photodynamic therapy (PDT) is getting attention treatment method all over the world. As it overviewed in article among others strategies this technique useful of diseases a wide range disciplines: dermatology, urology, gynecology, as well head and neck cancers age-related macular degeneration. Recently, development focused on looking for new photosensitizers optimizing dosimetry. Current articles report that PDT many cases significant supply conventional protocols but more than once can be...
Fibroblast growth factor receptor 1 (FGFR1) transmits signals through the plasma membrane regulating essential cellular processes like division, motility, metabolism, and death. Overexpression of FGFR1 is observed in numerous tumors thus constitutes an attractive molecular target for selective cancer treatment. Targeted anti-cancer therapies aim precise delivery drugs into cells, sparing healthy ones limiting unwanted side effects. One key steps targeted drug receptor-mediated endocytosis....
Antibody drug conjugates (ADCs) represent one of the most promising approaches in current immuno-oncology research. The precise delivery cytotoxic drugs to cancer cells using ADCs specific for tumor-associated antigens enables sparing healthy and thereby reduces unwanted side effects. Overexpression fibroblast growth factor receptor 1 (FGFR1) has been demonstrated numerous tumors constitutes a convenient molecular target selective treatment. We have recently engineered tetravalent anti-FGFR1...
With a wide range of available cytotoxic therapeutics, the main focus current cancer research is to deliver them specifically cells, minimizing toxicity against healthy tissues. Targeted therapy utilizes different carriers for drugs, combining targeting molecule, typically an antibody, and highly toxic payload. For effective delivery such conjugates, molecular target on cell required. Various proteins are exclusively or abundantly expressed in making possible drug carriers. Fibroblast growth...
Cancer drug resistance is a common, unpredictable phenomenon that develops in many types of tumors, resulting the poor efficacy current anticancer therapies. One most and yet complex causes mechanism related to dysregulation tumor cell signaling. Abnormal signal transduction cancer often stimulated by growth factors their receptors, including fibroblast (FGFs) FGF receptors (FGFRs). Here, we investigated effect FGF1 FGFR1 activity on action drugs disrupt tubulin polymerization (taltobulin,...
Breast cancer is a widespread and complex disease characterized by abnormal signaling pathways that promote tumor growth progression. Despite significant medical advances the development of increasingly effective therapies for breast cancer, drug resistance reduced sensitivity to prior remain persistent challenges. Dysregulation factors such as FGFs EGF their receptors contributing factor response treatment, promoting cell survival proliferation, metastasis, EMT or increased expression ABC...
Targeted therapies are a promising alternative to conventional chemotherapy, with an increasing number of therapeutics targeting specific molecular aberrancies in cancer cells. One the emerging targets for directed treatments is fibroblast growth factor receptors (FGFRs), which known be involved pathogenesis and progression multiple types, specially lung, bladder, breast cancers. Here, we demonstrating development FGFR1-targeting agent based on interactome screening approach, isolation...
Chemoresistance of cancer cells, resulting from various mechanisms, is a significant obstacle to the effectiveness modern therapies. Targeting fibroblast growth factors (FGFs) and their receptors (FGFRs) becoming crucial, as high activity significantly contributes development progression by driving cell proliferation activating signaling pathways that enhance drug resistance.
Abstract Fibroblast growth factor 1 (FGF1) acts by activating specific tyrosine kinase receptors on the cell surface. In addition to this classical mode of action, FGF1 also exhibits intracellular activity. Recently, we found that translocated into interior anti-apoptotic activity independent receptor activation and downstream signaling. Here, show expression increases survival cells treated with various apoptosis inducers, but only when wild-type p53 is present. The p53-negative were not...